Ultrasound contrast agent developer Sonus Pharmaceuticals announced today that it has entered into a memorandum of understanding with plaintiffs to settle all claims in the securities class-action lawsuit pending against the firm in federal court in Seattle. The settlement, to be funded by the Bothell, WA-based firm’s insurance carrier, is subject to approval by the court and the shareholder class.
By AuntMinnie.com staff writersJuly 31, 2000
Related Reading
Sonus reports profitable Q2 despite revenue shortfall, July 13, 2000.
FDA accepts Sonus response to EchoGen action letter, May 24, 2000.
Sonus takes over EchoGen rights, April 5, 2000.
Sonus gets another FDA action letter, March 14, 2000.
Sonus revises contrast deal with Abbott, February 17, 2000.
Nycomed payment buoys Sonus results, January 31, 2000.
Copyright © 2000 AuntMinnie.com